Oramed Pharmaceuticals 配当と自社株買い
配当金 基準チェック /26
Oramed Pharmaceuticals配当を支払う会社であり、現在の利回りは5.41%です。
主要情報
5.4%
配当利回り
2.9%
バイバック利回り
| 総株主利回り | 2.9% |
| 将来の配当利回り | n/a |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
Recent updates
Seeking Alpha • Dec 24
Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback
Summary Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new 60-patient trial. Positive results from ORMP's Chinese partner reinforce the potential for this narrower patient group. Validating the Protein Oral Delivery Platform in this subset could unlock broader applications beyond insulin. Read the full article on Seeking Alpha分析記事 • Nov 21
Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential
Investors appear disappointed with Oramed Pharmaceuticals Inc.'s ( NASDAQ:ORMP ) recent earnings, despite the decent...分析記事 • Nov 13
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • May 31
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Aug 24
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • May 03
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...分析記事 • Dec 22
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...Seeking Alpha • Sep 21
Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Summary Results from Oramed Pharmaceuticals's first phase 3 study ORA-D-013-1, using ORMD-0801 for the treatment of patients with Type 2 Diabetes, is expected January 2023. Results from the ongoing Cohorts A and B, using Oravax for Covid-19, are going to be read out Q3 and Q4 of 2022 respectively. An oral GLP-1 drug is being developed in the pipeline to treat patients with Type 2 Diabetes. The global Type 2 Diabetes market opportunity could double to $58.7 billion by 2025. Oramed Pharmaceuticals (ORMP) is a great speculative biotech play to look into. The reason why I state that is because it is developing an oral insulin drug, known as ORMD-0801 for the treatment of patients with Type 2 Diabetes. The reason why I think it can provide traders/investors an opportunity is because it is gearing up to report results from its phase 3 study using this drug for this patient population in January of 2023. This will be results from a late-stage study known as ORA-D-013-1. It did present preliminary results from the use of ORMD-0801 for the treatment of patients with non-alcoholic steatohepatitis ((NASH)) about a week ago. However, the primary endpoint was just looking at safety. The secondary endpoint of liver fat reduction at 12 weeks was not revealed. Just that there was a positive trend in favor of ORMD-0801. It remains to be seen if this NASH indication can be moved forward, but regardless the entire future of this biotech hinges on the phase 3 study using ORMD-0801 for the treatment of patients with Type 2 Diabetes. Even then, it does have a backup clinical candidate in the pipeline known as ORMD-0901 which is an oral GLP-1 analog. There are many other biotechs though who are targeting GLP-1, so whether or not this drug eventually shatters the competition remains to be seen. Still, it is nice to see that this biotech it at least working on another drug to target Type 2 diabetes. There is a final opportunity in developing an oral virus like particle ((VLP)) Covid-19 vaccine known as Oravax. Data is supposed to be out in Q3 of 2022 and then again Q4 of 2022. While not guaranteed for success, it is nice to see another shot on goal in the pipeline. However, the broader strategy here is to apply oral vaccine technology towards other indications that would typically require a vaccine. If somewhat successful with Covid-19, then it's possible to explore such other vaccine indications. Oral Insulin For Type 2 Diabetes Might Become A Reality The first program to go over involves the use of ORMD-0801 for the treatment of patients with Type 2 Diabetes. Type 2 Diabetes occurs as when the body is unable to use insulin properly to control sugar in the bloodstream. This is a larger market opportunity for sure. The reason why I state that is because T2D occurs in 95% of people with diabetes. Some symptoms of Type 2 Diabetes are: Blurry vision Fatigue Extreme thirst Frequent urination As I noted before, this is a very large market opportunity. It is expected that the global market opportunity could double to $58.7 billion by 2025. This is a very good opportunity for Oramed Pharma. In order for Oramed to eventually obtain FDA approval for ORMD-0801 for the treatment of patients with T2D, it has to succeed in one or both of the two ongoing phase 3 studies it has. The first phase 3 study which is currently ongoing is known as ORA-D-013-1. The goal for this trial was to enroll at least 675 patients, but happy to say that they were able to go over targeted enrollment to 710 patients. The primary endpoint of this study is improvement of glycemic control as assessed by A1c over a 26 week period. The secondary endpoint of this late-stage study is a change from baseline in fasting plasma glucose at 26 weeks. As far as a catalyst goes for this program, it is expected that topline results from the phase 3 ORA-D-013-1 study using ORMD-0801 for the treatment of patients with T2D, will be released by January of 2023. First and foremost, the biotech must meet the primary endpoint to succeed for this particular study. Of course, it may also have to do well in the 2nd phase 3 trial I will talk about below. However, should the drug do well in both studies and receive FDA approval, then it will have a few competitive advantages. One competitive advantage being that the drug is given orally instead of as an injection which is a huge improvement to quality of life. It just makes sense, patients would much rather take a drug orally instead of being injected. Secondly, the fact that it is given orally may give an advantage in terms of efficacy. That's because the drug starts to work even before reaching the patient's bloodstream. Lastly, the use of ORMD-0801 for T2D may have an advantage in terms of safety risks. Injectable insulin currently available on the market may cause weight gain and hypoglycemia (lower blood sugar range away from normal). Hopefully Oramed Pharma is successful, because it holds the potential to have the first FDA approved oral insulin drug. It would be huge, because the company already sees that an oral insulin drug would do well from a survey that was done. Such an IQVIA market survey showed that about 76% of physicians would likely prescribe oral insulin instead of injections. In order to really assess whether or not ORMD-0801 is capable of helping patients with T2D, it has an ongoing second phase 3 study in which it is advancing, known as ORA-D-013-2. This trial is expected to enroll up to a total of 450 Type 2 Diabetes patients. These are patients who don't receive an adequate glycemic control by diet only or diet and metformin monotherapy. This late-stage study is a double-blind trial that intends to randomize patients 1:1 into two specific cohorts: One cohort of patients receiving 8 mg ORMD-0801 at night Another cohort of patients receiving once placebo drug at night The primary endpoint here is no different than the primary endpoint for the first phase 3 ORA-D-013-1 study noted above. That is, the efficacy of ORMD-0801 will be compared to placebo in terms of improving glycemic control as assessed by A1c over a 26 week treatment period. The secondary endpoint will be the comparing of ORMD-0801 to placebo in maintaining glycemic control over a 52-week treatment period. I will state that this program could be a bit of a wait. The main topline data in January of 2023 will be crucial of course to see if ORMD-0801 is successful in treating patients with T2D. The problem is that this second phase 3 study will take a big longer. Looking at clinicaltrials site the estimated primary completion date for it is not until at least April of 2023. This means that data from this particular study may not be available until the 2nd half of 2023. Additional Shots On Goal As I indicated above, Oramed is also exploring the use of oral drug ORMD-0801 for the treatment of patients with NASH. Oramed did report preliminary results from the phase 2 study. However, I believe that its future with respect to this indication remains to be seen. The reason why I state that is because of course the safety was reported to be good, the problem is that there was no mention of what the actual percentage of liver fat reduction was. Measurements such as MRI PDFF(%) by MRI, steatosis and fibrosis measured by FibroScan, lipids and HbA1c all showed clinically meaningful trends in favor of ORMD-0801. To be fair, the secondary endpoint was made to assess efficacy in reducing liver fat content in patients with NASH and T2D in a non-statistically significant manner. I believe there is more proof of concept to be done here, therefore, if it does advance forward it would be a great bonus for the pipeline. I would have liked to at least seen some numbers over the 12-week period. While Oramed does have the two ongoing phase 3 studies using ORMD-0801 for the treatment of patients with Type 2 Diabetes, it is not leaving this drug as the only chance of moving a candidate forward for this indication. Having said that, it is pushing forward with a GLP-1 analog for Type 2 Diabetes. There, however, are two specific issues to be aware of though. The first issue being that this drug, known as ORMD-0901, is only being tested in a phase 1 for starters. Secondly, there are a host of competitors who are also developing their very own oral GLP-1 drug. I just wrote an article on Pfizer (PFE) discussing that the big pharma is gearing towards presenting data for its own oral small molecule GLP-1 drug for diabetes. The main premise is that it intends to hold an analyst and investor webcast presentation of oral GLP-1 data at the European Association for the Study of Diabetes (EASD) 2022. This data is going to presented on Wednesday, September 21, 2022 at 4:30 p.m. EDT. There are many other companies with GLP-1 agonists who currently have a portion of the market. Such companies are Novo Nordisk (NVO), Eli Lilly (LLY), AstraZeneca (AZN) and Sanofi (SNY).Seeking Alpha • Sep 09
Oramed to hand Korean rights for insulin capsule
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), a company focused on treatments for diabetes, announced a non-binding agreement with Medicox Co., Ltd. granting the latter exclusive right and license to seek regulatory nod and distribute ORMP’s oral insulin capsule ORMD-0801 in South Korea. The non-binding memorandum of agreement is only for discussion purposes and forms the basis for a definitive distribution license agreement, ORMP said in a regulatory filing Thursday. The 10-year deal includes a transfer price per capsule, milestone, and royalty payments. ORMP has also received a $2M non-refundable payment from Medicox in connection with an undertaking not to grant distribution and license rights to ORMD-0801 in the Republic of Korea until Dec. 15, 2022. The company expects an early 2023 topline data readout for ORMD-0801 from an ongoing Phase 3 trial in type 2 diabetes ahead of a potential submission of a marketing application to the FDA in 2024.Seeking Alpha • Jul 07
Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Oramed Pharmaceuticals (NASDAQ:ORMP), a clinical-stage pharma focused on diabetes and liver diseases, announced on Thursday that despite the challenges in enrollment, the company plans to share data from its Phase 1 trial for oral COVID-19 shot Oravax in 3Q 2022. Issuing a letter to shareholders, Oramed (ORMP) Chief Executive Nadav Kidron noted that the company introduced an additional clinical site amid slower than anticipated enrollment. Oramed (ORMP) has completed the enrollment and dosing in Cohort A with no safety issues so far. While topline data for Cohort A are expected in 3Q, plans are underway to achieve the enrollment target for the Cohort B within this quarter, with data anticipated in 4Q 2022. Recording $169M in cash and Investments as of March 31, Oramed (ORMP) said its cash runway would be adequate to complete the pivotal Phase 3 trials for ORMD-0801 towards a potential FDA approval of the oral insulin candidate. In December, Oramed (ORMP) announced that its subsidiary, Oravax Medical signed an agreement with a Vietnam-based company to sell its oral COVID-19 vaccine in Southeast Asia.分析記事 • Jun 12
Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Seeking Alpha • Apr 14
Oramed And Oral Insulin: Can This Small Company Really Do It?
Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity. This is a $15bn market, and there is very little competition.分析記事 • Feb 23
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Dec 23
Oramed And The Hurdles Of Developing Oral Insulin
Oramed is a leading developer of an oral formulation of human insulin. It uses a permeability enhancer to enable intestinal absorption. A recent cash raise caused the stock to fall drastically.分析記事 • Nov 02
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Oct 04
Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Giant pharma Merck's co-developed oral coronavirus drug with Ridgeback Biotherapeutics has raised interest in non-injected vaccine alternatives. The space was already occupied by Oramed, a clinical-stage biotech, whose oral vaccine is based on its POD technique, together with India's Premas Biotech COVID technology. This is a huge market, but also a highly competitive one due to the sheer number of biotechs involved, but the Israeli company can use previous experience in diabetes and NASH. Still, the fact that its shares have been adversely impacted after Merck's update shows that investors suffered from acidity when digesting the news. I remain bullish on this diversified stock, with market action also showing that its shares have been less battered than for established COVID biotechs.分析記事 • Aug 24
We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
We have been pretty impressed with the performance at Oramed Pharmaceuticals Inc. ( NASDAQ:ORMP ) recently and CEO...分析記事 • Jul 21
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, Oramed...決済の安定と成長
配当データの取得
安定した配当: ORMPの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: ORMPの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Oramed Pharmaceuticals 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (ORMP) | 5.4% |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Pharmaceuticals) | 2.2% |
| アナリスト予想 (ORMP) (最長3年) | n/a |
注目すべき配当: ORMPの配当金 ( 5.41% ) はUS市場の配当金支払者の下位 25% ( 1.41% ) よりも高くなっています。
高配当: ORMPの配当金 ( 5.41% ) はUS市場 ( 4.21% ) の配当支払者の中で上位 25% に入っています。
株主への利益配当
収益カバレッジ: ORMPの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: ORMPが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/11 21:46 |
| 終値 | 2026/05/11 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Oramed Pharmaceuticals Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4
| アナリスト | 機関 |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Edward Nash | Canaccord Genuity |
| Robert LeBoyer | Ladenburg Thalmann & Company |